NasdaqGS - Nasdaq Real Time Price USD
MaxCyte, Inc. (MXCT)
2.2000
-0.0700
(-3.08%)
At close: June 13 at 4:00:00 PM EDT
2.2800
+0.08
+(3.64%)
After hours: June 13 at 6:09:22 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
37,675
38,627
41,288
44,261
33,894.1000
Cost of Revenue
7,194
7,100
4,742
5,098
3,647.4000
Gross Profit
30,481
31,527
36,546
39,163
30,246.7000
Operating Expense
81,698
82,724
84,845
66,524
48,435.3000
Operating Income
-51,217
-51,197
-48,299
-27,361
-18,188.6000
Net Non Operating Interest Income Expense
9,427
10,142
10,376
3,917
-893.6000
Other Income Expense
--
--
--
-127
--
Pretax Income
-41,790
-41,055
-37,923
-23,571
-19,082.2000
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-41,790
-41,055
-37,923
-23,571
-19,082.2000
Diluted NI Available to Com Stockholders
-41,790
-41,055
-37,923
-23,571
-19,082.2000
Basic EPS
-0.40
-0.39
-0.37
-0.23
-0.21
Diluted EPS
-0.40
-0.39
-0.37
-0.23
-0.21
Basic Average Shares
105,314.4020
104,849.2220
103,268.5020
101,702.6640
90,619.0570
Diluted Average Shares
105,314.4020
104,849.2220
103,268.5020
101,702.6640
90,619.0570
Total Operating Income as Reported
-51,217
-51,197
-48,299
-27,361
-18,188.6000
Total Expenses
88,892
89,824
89,587
71,622
52,082.7000
Net Income from Continuing & Discontinued Operation
-41,790
-41,055
-37,923
-23,571
-19,082.2000
Normalized Income
-41,790
-41,055
-37,923
-23,571
-19,082.2000
Interest Income
9,427
10,142
10,376
3,917
150.8000
Interest Expense
116
--
--
126.9000
1,044.4000
Net Interest Income
9,427
10,142
10,376
3,917
-893.6000
EBIT
-51,217
-51,197
-48,299
-27,361
-18,037.8000
EBITDA
-46,377
-46,407
-43,733
-24,663
-16,613.9000
Reconciled Cost of Revenue
6,490
6,453
4,161
4,928
3,572.6000
Reconciled Depreciation
4,840
4,790
4,566
2,698
1,423.9000
Net Income from Continuing Operation Net Minority Interest
-41,790
-41,055
-37,923
-23,571
-19,082.2000
Normalized EBITDA
-46,377
-46,407
-43,733
-24,663
-16,613.9000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 7/30/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RPID Rapid Micro Biosystems, Inc.
3.5500
-1.66%
CTKB Cytek Biosciences, Inc.
3.2200
-4.17%
ZENI.ST Zenicor Medical Systems AB
2.5600
+1.59%
0O5H.IL Elekta AB (publ)
48.26
-1.86%
VSD-B.ST VibroSense Dynamics AB ser. B
1.9200
-4.00%
CLS-B.ST Clinical Laserthermia Systems AB (publ)
2.6600
-4.83%
CLPT ClearPoint Neuro, Inc.
11.54
-4.47%
QLINEA.ST Q-linea AB (publ)
0.0454
-2.78%
SEDANA.ST Sedana Medical AB (publ)
10.50
-3.14%
MX1.AX Micro-X Limited
0.0440
-8.33%